Table 2. Summary of Studies Assessing Hepatic Steatosis Using CAP.

Study	N	Probe	Reference Standard	Target Degree of Steatosis	Optimal Cutoff (dB/m)	AUROC	Sen (%)	Spe (%)
Sasso et al. [19]	115	M	Biopsy	≥ S1 (10%)	238	0.91	91	81
				≥ S2	259	0.95	89	86
				≥ S3	292	0.89	100	78
de Lédinghen et al. [73]	112	M	Biopsy	≥ S1 (10%)	266	0.84	69	85
				≥ S2	311	0.86	57	94
				≥ S3	318	0.93	87	91
Myers et al. [74]	153	M	Biopsy	≥ 10%	283	0.81	76	79
				≥ S1 (5%)	289	0.79	68	88
				≥ S2	288	0.76	85	62
				≥ S3	283	0.70	94	47
Masaki et al. [75]	155	M	Biopsy	≥ S1 (5%)	233	0.88	87	77
Chan et al. [76]	161	M	Biopsy	≥ S1 (5%)	263	0.97	92	94
				≥ S2	263	0.86	97	68
				≥ S3	281	0.75	100	53
Chon et al. [77]	135	M	Biopsy	≥ S1 (5%)	250	0.89	73	95
				≥ S2	299	0.89	82	86
				≥ S3	327	0.80	78	84
Shen et al. [78]	152	M	Biopsy	≥ S1 (5%)	253	0.92	89	83
				≥ S2	285	0.92	93	83
				≥ S3	310	0.88	92	79
Karlas et al. [79]	65	M	Biopsy	≥ S1 (5%)	234	0.93	93	87
				≥ S2	269	0.94	97	81
				≥ S3	301	0.82	82	76
de Lédinghen et al. [80]	261	M	Biopsy	≥ S2	310	0.80	79	71
				≥ S3	311	0.66	87	47
Eddowes et al. [81]	380	M, XL	Biopsy	≥ S1 (5%)	302	0.87	80	83
				≥ S2	331	0.77	70	76
				≥ S3	337	0.70	72	63
Oeda et al. [82]	122	M	Biopsy	≥ S2	267	0.64	93	36
				≥ S3	286	0.69	90	43
		XL	Biopsy	≥ S2	273	0.68	96	32
				≥ S3	302	0.71	84	48
Caussy et al. [83]	100	M	MRI-PDFF	≥ 5%	294	0.84	75	78
				≥ 10%	311	0.89	79	85
		XL	MRI-PDFF	≥ 5%	307	0.86	74	75
				≥ 10%	322	0.93	83	87

AUROC = area under the receiver operating characteristic curve, CAP = controlled attenuation parameter, PDFF = proton density fat fraction, Sen = sensitivity, Spe = specificity